Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt. As compared to prior year Q2 IDEFIRIX product sales increased 76%. LUND, Sweden, July 17, 2025 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced…
